ArticleNature immunology2020
ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung.
Article in Nature immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 155 citations in OpenAlex.
- IL-33/IL1RL1 (ST2) signalling drives immune suppression in squamous intraepithelial hyperplasia.Tumour virus research · 2026Article
- Tissue adaptation of eosinophils.Journal of leukocyte biology · 2026Review
- Review
- ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026Review
- IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Metabolically reprogrammed eosinophils impair T cell immunity and cause chronic skin infection.EMBO molecular medicine · 2026Article
- Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1/tissue-resident NK cell differentiation.Nature communications · 2026Article
- Involvement of increased arginase-1The Journal of international medical research · 2026Article
- Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.Nature communications · 2026Article
- The context-dependent role of group 2 innate lymphoid cells in lung diseases.Acta biochimica et biophysica Sinica · 2026Review
- Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarisedCommunications medicine · 2026Article
- Eosinophils in lung cancer: from inflammatory cytokines to immunotherapeutic biomarkers.Frontiers in immunology · 2026Review
- Unlocking IL-33: New Insights into Tumor Immunity.Immune network · 2025Review
- Cellular Cosmetics: How Innate Lymphoid Cells Can Recontour the Tumour Microenvironment.European journal of immunology · 2025Review
- Functional targeting of ILC2s and ILC3s reveals selective roles in intestinal fibrosis and homeostasis.The Journal of experimental medicine · 2025Article
- Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development.Cancer immunology research · 2025Article
- Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8Cancer immunology, immunotherapy : CII · 2025Article
- Cell-intrinsic metabolic phenotypes identified in patients with glioblastoma, using mass spectrometry imaging ofNature metabolism · 2025Article
- Cancer immune evasion, immunoediting and intratumour heterogeneity.Nature reviews. Immunology · 2025Review
- The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLCBiomolecules · 2025Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors at 6 institutions in 2 countries.
Funding
Abstract
Metastasis constitutes the primary cause of cancer-related deaths, with the lung being a commonly affected organ. We found that activation of lung-resident group 2 innate lymphoid cells (ILC2s) orchestrated suppression of natural killer (NK) cell-mediated innate antitumor immunity, leading to increased lung metastases and mortality. Using multiple models of lung metastasis, we show that interleukin (IL)-33-dependent ILC2 activation in the lung is involved centrally in promoting tumor burden. ILC2-driven innate type 2 inflammation is accompanied by profound local suppression of interferon-γ production and cytotoxic function of lung NK cells. ILC2-dependent suppression of NK cells is elaborated via an innate regulatory mechanism, which is reliant on IL-5-induced lung eosinophilia, ultimately limiting the metabolic fitness of NK cells. Therapeutic targeting of IL-33 or IL-5 reversed NK cell suppression and alleviated cancer burden. Thus, we reveal an important function of IL-33 and ILC2s in promoting tumor metastasis via their capacity to suppress innate type 1 immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.